{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:04Z","timestamp":1793262004856,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Australian Government\u2019s Medical Research Future Fund"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.atherosclerosis.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T03:08:25Z","timestamp":1589944105000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?"],"prefix":"10.1016","volume":"304","author":[{"given":"Zanfina","family":"Ademi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sijbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jpeds.2015.11.019","article-title":"Prevalence of familial hypercholesterolaemia in adolescents: potential value of universal screening?","volume":"170","author":"Pang","year":"2016","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.05.007_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the international FH foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"36","key":"10.1016\/j.atherosclerosis.2020.05.007_bib4","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2020.05.007_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOL.0000000000000365","article-title":"Challenges in the health economics of familial hypercholesterolemia","volume":"27","author":"Norman","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.ijcard.2013.01.280","article-title":"A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia","volume":"167","author":"Ademi","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2020.05.007_bib7","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart DiseaseA mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib8","series-title":"Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC)","author":"Health Do","year":"2016"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.05.007_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jpc.13898","article-title":"Parent-child genetic testing for familial hypercholesterolaemia in an Australian context","volume":"54","author":"Pang","year":"2018","journal-title":"J. Paediatr. Child Health"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2020.05.007_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.007_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","article-title":"Population trends of recurrent coronary heart disease event rates remain high","volume":"4","author":"Briffa","year":"2011","journal-title":"Circ.Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2018.04.040","article-title":"Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register","volume":"274","author":"Humphries","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib13","series-title":"General Record of Incidence of Mortality","year":"2018"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.007_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40272-014-0116-y","article-title":"Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence","volume":"17","author":"Braamskamp","year":"2015","journal-title":"Paediatric drugs"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.05.007_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","article-title":"Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia","volume":"8","author":"Ademi","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Publ. Health"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.007_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","article-title":"Health-related quality of life measured using the EQ-5D-5L: south Australian population norms","volume":"14","author":"McCaffrey","year":"2016","journal-title":"Health Qual. Life Outcome"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.007_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","article-title":"Acute and chronic impact of cardiovascular events on health state utilities","volume":"15","author":"Matza","year":"2015","journal-title":"BMC Health Serv. Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.007_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.007_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacl.2019.01.010","article-title":"LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia","volume":"13","author":"Bogsrud","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.05.007_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jacl.2017.01.002","article-title":"Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia","volume":"11","author":"Lazaro","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2020.05.007_bib25","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/eurheartj\/ehx111","article-title":"Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK","volume":"38","author":"Kerr","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.atherosclerosis.2018.01.036","article-title":"The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland","volume":"270","author":"Pelczarska","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijcard.2014.12.070","article-title":"Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States","volume":"181","author":"Chen","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2018.05.047","article-title":"Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis","volume":"275","author":"McKay","year":"2018","journal-title":"Atherosclerosis"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2020.05.007_bib29","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2020.05.007_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacl.2017.11.009","article-title":"Treatment goal attainment in children with familial hypercholesterolemia: a cohort study of 302 children in Norway","volume":"12","author":"Bogsrud","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.05.007_bib31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1177\/2047487318817910","article-title":"Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective","volume":"26","author":"Zomer","year":"2019","journal-title":"Eur. J. Prevent. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.05.007_bib32","series-title":"Is Prevention Better than Cure?","first-page":"134","author":"Russell","year":"1986"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.05.007_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/jpm9030032","article-title":"Barriers and facilitators to genetic testing for familial hypercholesterolemia in the United States: a review","volume":"9","author":"Hendricks-Sturrup","year":"2019","journal-title":"J. Personalized Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020302604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:09Z","timestamp":1762187109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020302604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"alternative-id":["S0021915020302604"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.007","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}